*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ The/DT U.S./NNP Food/NNP ]
and/CC 
[ Drug/NNP Administration/NNP ]
approved/VBD 
[ Merck/NNP ]
&/CC 
[ Co./NNP 's/POS new/JJ ulcer/NN drug/NN ]
,/, 
[ Losec/NNP ]
,/, for/IN 
[ limited/JJ use/NN ]
in/IN treating/VBG 
[ rare/JJ disorders/NNS ]
caused/VBN by/IN 
[ gastrointestinal/JJ acid/NN ]
./. 

======================================

[ The/DT FDA/NNP ]
decided/VBD to/TO initially/RB restrict/VB 
[ Losec/NNP 's/POS use/NN ]
until/IN 
[ Merck/NNP ]
conducts/VBZ 
[ extensive/JJ studies/NNS ]
regarding/VBG 
[ the/DT drug/NN 's/POS long-term/JJ safety/NN ]
./. 

[ Losec/NNP ]
is/VBZ expected/VBN eventually/RB to/TO gain/VB 
[ wide/JJ use/NN ]
in/IN treating/VBG 
[ mild/JJ ]
to/TO 
[ severe/JJ ulcers/NNS ]
and/CC to/TO provide/VB 
[ an/DT alternative/NN ]
to/TO 
[ Tagamet/NNP ]
and/CC 
[ Zantac/NNP ]
,/, 
[ the/DT ]
most/RBS commonly/RB prescribed/VBN 
[ medicines/NNS ]
,/, 
[ which/WDT ]
have/VBP combined/VBN 
[ world-wide/JJ sales/NNS ]
of/IN about/RB 
[ $/$ 3/CD billion/CD ]
./. 

======================================

[ The/DT FDA/NNP approval/NN ]
for/IN 
[ Losec/NNP ]
only/RB allows/VBZ 
[ its/PRP$ use/NN ]
in/IN treating/VBG 
[ inflammations/NNS ]
of/IN 
[ the/DT esophagus/NN ]
and/CC 
[ stomach/NN lining/NN ]
,/, 
[ which/WDT ]
cause/VBP 
[ a/DT symptom/NN ]
similar/JJ to/TO 
[ severe/JJ heartburn/NN ]
,/, and/CC in/IN treating/VBG 
[ a/DT rare/JJ condition/NN ]
,/, known/VBN as/IN 
[ Zollinger-Ellison/NNP Syndrome/NNP ]
,/, caused/VBN by/IN 
[ excessive/JJ secretion/NN ]
of/IN 
[ gastric/JJ acids/NNS ]
./. 

In/IN 
[ March/NNP ]
,/, 
[ an/DT advisory/JJ committee/NN ]
to/TO 
[ the/DT FDA/NNP ]
recommended/VBD 
[ the/DT restricted/VBN approval/NN ]
because/IN 
[ an/DT early/JJ study/NN ]
of/IN 
[ the/DT drug/NN ]
in/IN 
[ laboratory/NN animals/NNS ]
produced/VBD 
[ some/DT cases/NNS ]
of/IN 
[ cancer/NN ]
./. 

[ Human/JJ studies/NNS ]
have/VBP yet/RB to/TO uncover/VB 
[ such/JJ problems/NNS ]
,/, but/CC 
[ the/DT FDA/NNP advisory/NN group/NN ]
said/VBD 
[ it/PRP ]
nonetheless/RB wanted/VBD 
[ lengthier/RBR safety/NN studies/NNS ]
./. 

======================================

[ Analysts/NNS ]

[ who/WP ]
follow/VBP 
[ the/DT pharmaceutical/JJ industry/NN ]
expect/VBP 
[ Losec/NNP ]
eventually/RB to/TO gain/VB 
[ approval/NN ]
for/IN 
[ wider/JJR use/NN ]
./. 

[ Merck/NNP ]
said/VBD 
[ it/PRP ]
expects/VBZ to/TO present/VB 
[ safety/NN data/NNS ]
to/TO 
[ the/DT FDA/NNP next/JJ year/NN ]
./. 

[ Robert/NNP Uhl/NNP ]
,/, 
[ an/DT analyst/NN ]
with/IN 
[ Salomon/NNP Bros./NNP ]
,/, said/VBD that/IN even/RB with/IN 
[ the/DT FDA/NNP restrictions/NNS ]
,/, 
[ many/JJ doctors/NNS ]
will/MD begin/VB using/VBG 
[ the/DT drug/NN ]
to/TO treat/VB 
[ patients/NNS whose/WP$ ulcers/NNS ]
do/VBP n't/RB respond/VB to/TO 
[ Tagamet/NNP ]
or/CC 
[ Zantac/NNP ]
./. 

Once/RB 
[ a/DT drug/NN ]
is/VBZ approved/VBN for/IN 
[ sale/NN ]
,/, 
[ doctors/NNS ]
could/MD prescribe/VB 
[ it/PRP ]
for/IN 
[ ulcers/NNS ]
./. 

[ Merck/NNP ]
,/, however/RB ,/, is/VBZ n't/RB permitted/VBN to/TO market/VB 
[ Losec/NNP ]
to/TO 
[ doctors/NNS ]
as/IN 
[ a/DT common/JJ ulcer/NN treatment/NN ]
./. 

======================================

[ Mr./NNP Uhl/NNP ]
said/VBD 
[ Losec/NNP ]
may/MD generate/VB 
[ $/$ 100/CD million/CD ]
in/IN 
[ sales/NNS ]
for/IN 
[ Merck/NNP ]
in/IN 
[ 1990/CD ]
,/, rising/VBG to/TO 
[ $/$ 400/CD million/CD ]
by/IN 
[ 1992/CD ]
if/IN 
[ the/DT FDA/NNP ]
lifts/VBZ 
[ its/PRP$ restrictions/NNS ]
./. 

======================================

[ Losec/NNP ]
,/, known/VBN also/RB by/IN 
[ the/DT generic/JJ name/NN omeprazole/NN ]
,/, was/VBD developed/VBN by/IN 
[ a/DT division/NN ]
of/IN 
[ Swedish/JJ drug/NN maker/NN AB/NNP Astra/NNP ]
,/, 
[ which/WDT ]
sells/VBZ 
[ the/DT drug/NN ]
in/IN about/RB 
[ 10/CD European/JJ countries/NNS ]
./. 

[ Rahway/NNP ]
,/, 
[ N.J.-based/JJ Merck/NNP ]
holds/VBZ only/RB 
[ the/DT U.S./NNP ]
marketing/NN 
[ rights/NNS ]
to/TO 
[ the/DT drug/NN ]
./. 

[ A/DT European/JJ study/NN ]
,/, published/VBN 
[ January/NNP ]
in/IN 
[ the/DT New/NNP England/NNP Journal/NNP ]
of/IN 
[ Medicine/NNP ]
,/, said/VBD 
[ Losec/NNP ]
healed/VBD 
[ a/DT greater/JJR proportion/NN ]
of/IN 
[ ulcers/NNS ]
faster/RBR and/CC kept/VBD 
[ them/PRP ]
healed/VBN longer/RBR than/IN 
[ Zantac/NNP ]
,/, 
[ which/WDT ]
is/VBZ sold/VBN by/IN 
[ Glaxo/NNP PLC/NNP ]
of/IN 
[ Great/NNP Britain/NNP ]
./. 

======================================

[ Sources/NNS ]
close/JJ to/TO 
[ the/DT FDA/NNP ]
said/VBD 
[ the/DT agency/NN ]
is/VBZ impressed/VBN by/IN 
[ Losec/NNP 's/POS effectiveness/NN ]
and/CC is/VBZ worried/VBN that/IN if/IN 
[ the/DT FDA/NNP ]
granted/VBD 
[ an/DT unrestricted/JJ approval/NN ]
,/, 
[ doctors/NNS ]
might/MD use/VB 
[ the/DT drug/NN ]
in/IN 
[ great/JJ numbers/NNS ]
before/IN 
[ a/DT fuller/JJR safety/NN profile/NN ]
is/VBZ produced/VBN ./. 

[ The/DT FDA/NNP ]
``/`` hopes/VBZ 
[ the/DT limited/VBN label/NN ]
will/MD keep/VB use/NN down/RP until/IN 
[ everyone/NN ]
is/VBZ more/RBR comfortable/JJ with/IN 
[ the/DT drug/NN ]
,/, ''/'' 
[ the/DT FDA/NNP source/NN ]
said/VBD ./. 
